Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2a Study to Evaluate the Efficacy of BX003 in Reducing the Intestinal Bacterial Burden of Klebsiella Pneumoniae in Target Bacteria Carriers

Next Previous
Trial Profile

A Phase 1b/2a Study to Evaluate the Efficacy of BX003 in Reducing the Intestinal Bacterial Burden of Klebsiella Pneumoniae in Target Bacteria Carriers

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BX 003 (Primary)
  • Indications Klebsiella infections
  • Focus Therapeutic Use
  • Sponsors BiomX

Most Recent Events

  • 18 May 2021 According to a BiomX media release, results expected by the second quarter of 2022.
  • 02 Feb 2021 According to a BiomX media release, Phase 1b/2 trial of BX003 for the reduction of K. pneumonia will start based on data from this trial.
  • 26 Nov 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top